DAIHAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28,450 KRW | +0.53% |
|
+1.43% | +2.52% |
| 2023 | Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index | CI |
| 2023 | Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2024 * | 213B 155M | Sales 2025 * | 233B 169M | Capitalization | 167B 122M |
|---|---|---|---|---|---|
| Net income 2024 * | 30B 21.81M | Net income 2025 * | 33B 23.99M | EV / Sales 2024 * | 0.14 x |
| Net cash position 2024 * | 138B 100M | Net cash position 2025 * | 163B 119M | EV / Sales 2025 * | 0.02 x |
| P/E ratio 2024 * |
5.54
x | P/E ratio 2025 * |
5.14
x | Employees | 553 |
| Yield 2024 * |
2.46% | Yield 2025 * |
2.55% | Free-Float | 59.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.53% | ||
| 1 week | +1.43% | ||
| Current month | +0.53% | ||
| 1 month | +1.07% | ||
| 3 months | +1.97% | ||
| 6 months | +6.75% | ||
| Current year | +2.52% |
1 week
28 000.00
28 500.00
1 month
27 600.0028 550.00
Current year
27 450.0029 650.00
1 year
25 500.0030 300.00
3 years
24 250.0044 800.00
5 years
21 950.0047 700.00
10 years
16 050.0052 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
Seong-Soo Yoon
AUD | Comptroller/Controller/Auditor | 46 | 17-03-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Seung-Young Lee
BRD | Director/Board Member | 51 | 02-02-28 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 28,450 | +0.53% | 4,760 |
| 24-04-25 | 28,300 | -0.70% | 3,847 |
| 24-04-24 | 28,500 | +0.18% | 5,109 |
| 24-04-23 | 28,450 | +0.71% | 10,151 |
| 24-04-22 | 28,250 | +0.71% | 2,686 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
DAIHAN PHARMACEUTICAL CO.,LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The Company provides infusions, including basic infusions, nutritional infusions and infusions for special uses; injections for anesthetics, vitamin-minerals, autonomic nerve systems, hypnotic-sedatives, antispasmodics, antidotes, hormones, analgesics, respiratory and others; contrast media, such as drugs for computed tomography (CT) uses and magnetic resonance imaging (MRI) uses, and other drugs, such as drugs for irrigations, ointments, inhalants, as well as quasi-drugs such as hand gels, lens clean solutions and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.52% | 121M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B |
- Stock Market
- Equities
- A023910 Stock
